

Clinicians are right to demand more from a super-absorbent dressing.

Highly exuding wounds are demanding for both clinician and patient: excess fluid can make achieving an optimum moisture balance difficult, leakage is uncomfortable and can lead to maceration and the constituents of wound fluid, including bacteria and matrix metalloproteinases (MMPs), can be an impediment to wound healing.

3M™ Kerramax Care™ Super-Absorbent Dressings with advanced Exu-Safe™ Technology, unique lateral wicking system and ability to sequester bacteria^{1,2*} and MMPs,^{3*} are ready to meet these demands helping to transform patient outcomes.

Kerramax Care Dressings: 3 demands clinicians can confidently make.

Demand

(1)

Effective Sequestration and Retention of Bacteria and MMPs

Demand

2

High Absorption and Protection for Patients


Demand

3

Dressings that Support Patient Comfort



Kerramax Care[™] Dressings.



Indications

Kerramax Care dressing is indicated for moderately to highly exuding:

- Pressure Injuries
- Venus Leg Ulcers
- Diabetic Foot Ulcers




Effective sequestration and retention of bacteria and

Because Kerramax Care dressings lock away exudate, even under pressure,^{7*} they are also effective at Exu-Safe Technology keeps these threats away from delicate wound tissue, wound edges and healthy

Pseudomonas aeruginosa and Staphylococcus aureus bacteria released by super-absorbent dressings.8*

In vitro studies have shown Kerramax Care dressing are superior in their ability to retain bacteria within the dressing.^{8*} In comparison, other superabsorbent dressings released between 6 and 171 million more bacteria back into the wound bed than Kerramax Care dressing.^{8*}

S. aureus and P. aeruginosa bacteria released from super-absorbent dressings.




Kliniderm® (H&R Healthcare Ltd), Vliwasorb® Pro (Lohmann & Rauscher GmbH), Zetuvit® Plus (Paul Hartmann AG), Mextra® (Mölnlycke Health Care AB) and ConvaMax™ (ConvaTec Group PLC).

Where does sequestered bacteria reside within the dressing?

In vitro studies^{1,8*} demonstrate that Kerramax Care dressings lock away bacteria within the dressing core away from the outer layers in direct contact with the wound bed.

Scanning electron microscope image of the outer layer of Kerramax Care dressing following application of bacteria demonstrating effective sequestration away from the wound contact layer.8*




MMPs.

locking away bacteria and MMPs present in wound fluid, which can delay wound healing. surrounding skin.

Sequestration of MMPs.9*

Samples of dressings were incubated with MMP2 or MMP9. After four days, the dressing samples were saturated and the MMPs released from the dressings were quantified.



Kliniderm® (H&R Healthcare Ltd), Vliwasorb® Pro (Lohmann & Rauscher GmbH), Zetuvit® Plus (Paul Hartmann AG), Mextra® (Mölnlycke Health Care AB) and ConvaMax™ (ConvaTec Group PLC).






High absorption and protection for patients.

All wounds produce exudate to help repair and heal damaged tissue. However, in non-healing, chronic wounds, excessive exudate production can be a problem. Whether exudate is serous or viscous, the combination of a unique horizontal wicking and Exu-Safe Technology ensures high fluid absorption and retention,⁴ even under compression.^{7*} For the patient, this reduces the risk of maceration.

Kerramax Care™ Dressings minimise this risk in three ways:



1. Horizontal wicking system, ensures exudate is absorbed evenly throughout the dressing, with no gel blocking, 6 which can lead to leaks.



2. High fluid absorption and retention capacity, to help lock bacteria and MMPs in the dressing's core, 1* away from the wound.



3. Heat-sealed border, to prevent exudate leakage from the dressing^{7*} and keep the dressing strong and intact.



Safely contain potential threats from chronic wound fluid.

Kerramax Care dressings offer an advanced method of absorbing fluid from wounds utilising the Exu-Safe Technology built into the dressing's core.



Locks away exudate to protect delicate wound tissue and surrounding skin.⁴



Locks away the transmission risk of infection^{2*} in chronic wounds.



Locks away harmful components of chronic wound fluid — especially bacteria.1*

Fluid



Can cause maceration if exudate comes into contact with peri-wound skin.

Bacteria




The presence of bacteria increases the risk of wound infection which can result in delayed healing.

MMPs



Can contribute to delayed healing and wound edge breakdown.



Locks away bacteria from the wound bed.1*

*As demonstrated in vitro.




Dressings to support patient comfort.

A positive patient experience can lead to reduced stress and anxiety when dealing with chronic wounds, this in turn can reduce pain and improve patient concordance with treatment.⁴ Kerramax Care dressings are designed for patient comfort. Their non-woven material is soft on skin and remains dry to the touch, due to Exu-Safe Technology.

Patient experience: patient comfort

In a recent patient study of managing highly exuding wounds in the community, Kerramax Care dressings were evaluated for patient experience based on comfort. A total of 101 patient evaluations were completed across a range of wound aetiologies.



Patients 71%

Scored the dressing between 8–10 highlighting a high level of comfort and positive patient experience.4

Clinicians 98%

Would use Kerramax Care
dressings as their first choice4
for the management of highly
exuding wounds.

Kerramax Care™ Dressings at a glance



Absorbs and retains high levels of exudate.7*



Soft, conformable and foldable.⁴



Sequesters bacteria^{2*} and MMPs.^{3*}



Easy to apply⁴ (using either side).



Can be used under all forms of compression. 5,7*



Can be left in place for seven days.

*As demonstrated in vitro

Ordering Information

3M [™] Kerramax Care [™] Super-Absorbent	Dressing		
Catalog ID	Size	Dressings Per Box	HCPCS
PRD500-025	2" x 2"	10 ea/bx	A6196
PRD500-050	4" × 4"	10 ea/bx	A6196
PRD500-100	5" x 6"	10 ea/bx	A6197
PRD500-120	4" x 9"	10 ea/bx	A6197
PRD500-240	8" x 9"	10 ea/bx	A6198
PRD500-380 -B10	8" x 12"	10 ea/bx	A6198
PRD500-600-B10	8" x 20"	10 ea/bx	A6198
3M [™] Kerramax Care [™] Gentle Border Dr	essing		
PRD500-1174	4" x 4"	10 ea/bx	A6196
PRD500-1175	6" x 6"	10 ea/bx	A6196
PRD500-1176	8" x 8"	10 ea/bx	A6197
PRD500-1177	6" x 10"	10 ea/bx	A6197

Contact your local 3M Account Manager, call the 3M Health Care Helpline at 1-800-228-3957, or visit 3M.com/Medical for more information.

Expertise along the exudate management continuum.

Dry to low ♦♦♦♦	Low to moderate ♦♦♦♦	Moderate to high ♦♦♦♢	High to very high ♦♦♦♦
3M™ Kerralite Cool™ Hydrogel Moisture Balancing Dressing Absorbent, moisture balancing hydrogel sheet dressing	3M™ Tegaderm™ Absorbent Clear Acrylic Dressing Conformable, absorbent clear dressing	3M™ Tegaderm™ Silicone Foam Border Dressing Silicone foam dressing with advanced adhesive technology 3M™ Kerracel™ Gelling Fiber Dressing Conformable, gelling fiber dressing	3M™ Kerramax Care™ Super-Absorbent Dressings Super-absorbent dressing with Exu-Safe™ Technology



3M Company 2510 Conway Avenue St. Paul, MN 55144-1000 USA

1-800-228-3957 3M.com/Medical



References

1. Cooper, R. An investigation into the ability of Kerramax Care" and Kerrafoam" to bind bacteria. Cardiff Metropolitan University. September 2013. 2. Thomas, H. & Westgate, S.J. An in vitro comparison of MRSA and P. aeruginosa sequestration by five super-absorbent wound dressings. Poster presented at EWMA; 11–13 May 2016; Bremen, Germany. 3. Dr. Cochrane, C.A. Evaluation of matrix metalloproteinsases by wound care products. University of Liverpool, UK. July 2011. 4. Hughes, M. A large-scale evaluation of managing moderate and highly exuding wounds in the community. Wounds UK. 2017;13(3):78–85. 5. Cotton, S. The management of a chronic leg ulcer using Kerramax Care" Super-Absorbent Dressing under compression. Poster presented at Wounds UK; November 2015; Harrogate, UK. 6. Rose, R. A large clinical evaluation assessing the tolerance & effectiveness of super-absorbent dressing, Kerramax Care" Poster presented at Wounds UK; November 2015; Harrogate, UK. 7. Jackson, S. & Warde, D. Determination of free swell absorption and fluid retention, and absorption capacity under would be, November 2013, Hairbgate, Or. P. Jackson, S. warde, B. Determination in the swell absorbed retention, and accomplication and accomplication pressure of Kerramax Care." Crawford Healthcare Ltd. CHC R596. Knutsford, UK: 2017. 8. Singh, G. & Thomason, H. Sequestration and retention of bacteria by superabsorbent dressings over time. KCl. CHC R1043 (in vitro). University of Manchester & KCl. Knutsford, UK. 2020. 9. Singh, G. & Thomason, H. Sequestration of matrix metalloproteinases (MMPs) by superabsorbent wound dressings. KCl. CHC R1042 (in vitro). University of Manchester & KCl Knutsford, UK. 2020.

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application.

© 2021 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. Used under license in Canada. PRA-PM-ALL-00301 (02/21) US_70-2011-8168-5